By Danny Sullivan – Longevity.Technology –
Initial focus on epilepsy could drive progress in aging and healthspan therapeutics targeting the mTOR pathway.
US biotech Aeovian Pharmaceuticals today secured a $55 million Series B funding round to advance its lead program in a rare form of epilepsy – a move that could ultimately shape how longevity-linked mTOR biology is therapeutically harnessed in aging and healthspan. The oversubscribed round, led by Luma Group, will fund completion of a Phase 2 proof-of-concept study of AV078, a selective mTORC1 inhibitor in tuberous sclerosis complex (TSC)-related refractory epilepsy.
